5 trends tracked about this subject — the full history, oldest to newest below.
Bristol Myers Squibb reports successful Phase 2 results for its next-generation GPRC5D-directed CAR-T therapy targeting heavily treated myeloma patients.
Novartis and Bristol Myers Squibb halt autoimmune CAR-T trials following patient deaths, impacting the sector.
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
AstraZeneca investors are resisting proposed acquisition talks with Bristol Myers valued at $400 billion.